pharmaceuticals

Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in oral and...

Earlier this week, Sarepta Therapeutics, Inc (NASDAQ:SRPT) provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in non-...

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

H.C. Wainwright analyst Brandon Folkes initiated coverage on Omeros Corporation (NASDAQ:OMER) with a Buy rating and a price forecast of $9. According to Brandon, Omeros holds significant long-term value potential due to its expansive rare disease pipeline. While the company has faced investor...

Arvinas, Inc. (NASDAQ:ARVN) on Friday announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE:PFE). The application covers vepdegestrant for patients with ER-positive (ER+)/human epidermal growth factor...

Verastem Oncology Inc (NASDAQ:VSTM) released on Monday updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients...

The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.’s (NASDAQ:ETON) new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric patients five years of age and older with adrenocortical insufficiency. Adrenocortical...

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares are trading lower Friday following the release of updated interim data from its Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma. What To know: The...

Merck & Co Inc (NYSE:MRK) on Thursday said the Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65), met its primary endpoint of progression-free survival (PFS) for platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers. The study also met a secondary...

Sanofi SA (NASDAQ:SNY) announced on Wednesday that it will invest at least $20 billion in the U.S. through 2030. Research and development, plus U.S. manufacturing, will receive the bulk of the spending. The company also expects higher job creation within the communities where Sanofi and its...

Septerna Inc. (NASDAQ:SEPN) and Novo Nordisk A/S (NYSE:NVO) announced an exclusive global collaboration and license agreement on Wednesday. The pact covers discovering, developing, and commercializing oral small-molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases....

GSK plc (NYSE:GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes $1.2 billion upfront, with the potential for additional success-based milestone payments...

Bayer AG (OTC:BAYRY) reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago. The company reported: Adjusted earnings of 65 cents, beating the consensus of 38 cents. Sales reached $14.45 billion (13.74 billion...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents. The biopharma company reported fourth-quarter sales of $62.47 million, up 24% year over year, almost in line with the...

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility. With President Donald Trump’s administration rehashing contentious ideas on drug...